Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities — (MARGARET)

RET-altered Non Small Cell Lung Cancer Clinical Trial

Official title:
Phase I/II Study of the Selective RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities

Status Recruiting

Clinical Trial Summary

Phase 1 and 2 trial to study the safety, pharmacokinetics, and efficacy of TAS0953/HM06 in patients with advanced solid tumors with RET gene abnormalities. Phase 1 aims to determine the Maximum Tolerated Dose (MTD) and identify the Recommended Phase 2 Dose (RP2D) to be used in phase 2.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04683250
Study type	Interventional
Source	Helsinn Healthcare SA
Contact	Michael Karl
Phone	+49 8709 943 761
Email	Michael.Karl@iconplc.com
Status	Recruiting
Phase	Phase 1/Phase 2
Start date	December 16, 2020
Completion date	September 2025

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT03037385` - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors	Phase 1/Phase 2
	Recruiting	`NCT05653869` - A Study of APS03118 in Advanced Solid Tumors Harboring RET Mutations or Fusions	Phase 1